Introduction
Obesity, particularly abdominal obesity, is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Obesity, defined by body mass index 30 kg/m 2 or greater, is rather weakly associated with increased risk of metabolic derangements, whereas intra-abdominal (mesenteric) fat accumulation is a far stronger predictor of impaired glycaemic control. 1, 2 Fortunately, there is good evidence that losing weight is an efficacious means of improving insulin sensitivity and hence decreasing risk of obesity-associated diabetes. Weight loss induced by such diverse means as gastric surgery, pharmacotherapy and lifestyle interventions, including exercise, all result in better glycaemic control and reduced risk of type 2 diabetes. [3] [4] [5] [6] In addition to insulin resistance, type 2 diabetes is also associated with impaired β-cell function. Thus the ideal antidiabetic therapy would improve glucose disposal and β-cell function while reducing body weight.
Agonists acting via stimulation of the GLP-1 receptor compose an interesting, innovative class of antihyperglycaemic agents as they address pancreatic function as well as caloric intake. 7, 8 Other articles in this publication thoroughly review direct and indirect actions of GLP-1 upon β-cell function (see Holst pp. S10-S18 and Gallwitz pp. S19-S25), whereas this article will concentrate on GLP-1 agonist-induced weight loss. Clinical experience obtained with the use of exenatide demonstrates that a certain subset of subjects with type 2 diabetes is particularly sensitive to GLP-1 agonist-induced weight loss, which appears to be robustly sustained. 9 Conversely, weight loss is not associated with inhibitors of DPP-4. Thus, it appears that higherthan-normal physiological levels of GLP-1 agonists are required to obtain the desired weight loss to overcome this inhibition.
The first hint of a potential role of endogenous GLP-1 in regulation of metabolic control was given by the observation that GLP-1 acts as an ileal brake by reducing gastric motility and hence delivery of calories to absorptive sections of the small intestine. 10 In humans, intravenous infusion of GLP-1 was demonstrated to decrease caloric intake and trigger premature satiety and sense of fullness. 11 A few years prior to these clinical pharmacological experiments, studies in rodents suggested that the brain is equipped with GLP-1-sensitive sites eliciting negative energy balance. Thus intracerebroventricular administration of GLP-1 has been shown to trigger a potent anorectic response, and upon repetitive administration, GLP-1 agonists have caused negative energy balance and weight loss. [12] [13] [14] [15] In rats, the half-life of intact biologically active GLP-1 is less than a minute. Hence, it took very large doses of either GLP-1(7-36NH 2 ) or once-daily, DPP-4-resistant, GLP-1-agonist liraglutide to provide evidence that peripheral administration of GLP-1 agonists induces anorexia and weight loss. 7 For several years, it has been evident that continuous activation of peripheral as well as central GLP-1 receptors induces lasting negative energy balance with resulting weight loss. The present review discusses the role of central nervous system GLP-1 receptors in energy homeostasis, as well as that of peripheral GLP-1 receptors. It will summarise current understanding in a therapeutic context to provide a thorough scientific perspective on improved weight control with agents acting via GLP-1 signalling pathways.
Central GLP-1 systems in energy homeostasis
The only GLP-1-containing nerve fibres in the brain are the distinct population of pre-proglucagon-expressing neurons located in the nucleus of the solitary tract. 16 The primary input to the brainstem GLP-1 neurons is via vagal afferents conveying sensory input from the lower gastrointestinal tract. The areas primarily targeted by brainstem GLP-1 efferents are the mediobasal hypothalamic nuclei and other areas of the limbic system involved in regulation of body weight homeostasis. Expression of the GLP-1 receptor has been detected in most of these target areas, and receptor autoradiographic studies have revealed a high degree of overlap between GLP-1-containing synaptic terminals and GLP-1 binding sites in the brain. 17, 18 However, in the context of understanding the role of preproglucagon-derived peptides and their role in energy homeostasis, some distinct mismatches exist. For example, high densities of GLP-1 binding sites are present in blood-brain-barrier-free circumventricular organs, but these areas are remarkably free of GLP-1-containing fibres. With regard to potential involvement of energy expenditure, the blood-brain-barrierfree circumventricular areas of greatest interest are the area postrema and the median eminence adjacent to the hypothalamic arcuate nucleus.
To further understand the physiological role of GLP-1 as an appetite suppressing neuropeptide mediating negative energy balance, a number of studies employing site-directed injection of GLP-1 into distinct hypothalamic nuclei have been undertaken. In rodents, direct administration of GLP-1 into the dorsomedial and paraventricular nuclei, as well as the lateral hypothalamic area, resulted in a dose-dependent decrease of feeding in the fasted state. 19 Concern has been raised that GLP-1-associated anorexia is merely a result of non-specific aversion. 20 However, this possibility seems unlikely, as GLP-1-induced anorexia elicited by site-directed injections into hypothalamic nuclei is not accompanied by aversive behaviours. In a search for hypothalamic target neurons of pivotal importance for GLP-1-induced anorexia, researchers at the University of Copenhagen studied rats in which the hypothalamic arcuate nucleus had been ablated by a neurochemical lesion with MSG. 21 The arcuate nucleus harbours two distinct populations of leptin-sensitive neurons: the anorexigenic POMC/CART neurons, and the orexigenic NPY/AGRP neurons. 22 Leptin mediates its acute anorectic action by activation of POMC/CART neurons and inhibition of NPY/AGRP neurons. Since these neurons are absent in MSG-lesioned rats, leptin had no impact on their feeding. 21 An image of current understanding of the central GLP-1 pathway involved in appetite regulation is presented in figure 1 .
Our understanding of which physiological stimuli are involved in triggering central GLP-1-mediated anorexia and negative energy balance is far from complete. Initially, experimental work with GLP-1R -/-mice led to the conclusion that GLP-1 receptors have no relevance in regulation of energy homeostasis. 23 Aside from emphasising that neuronal wiring responsible for defence of body energy reserves is redundant, careful scrutiny of feeding patterns revealed that GLP-1 receptor knockout mice stop eating much more slowly than their wild-type counterparts. This observation points towards a role of GLP-1 as a satiety signal from the gut to the brain. In fact, since mechanical distension of the stomach triggers activation of brainstem GLP-1-containing neurons, it appears that they may normally be involved in meal termination. 24 Expression of brainstem preproglucagon mRNA is elevated in rodents with defective leptin signalling, which suggests that the central GLP-1 pathway is part of a counter-regulatory neuronal pathway activated to dampen the positive energy balance due to hyperphagia. 25 The notion that increased central GLP-1 tone is present in leptin-signalling-deficient animals is supported by pharmacological evidence showing that central application of the GLP-1 receptor antagonist exendin-9-39 to Zucker rats results in excessive hyperphagia. 25 The common processing pattern of preproglucagon in the brainstem is similar to that present in enteroendocrine L cells. This pattern yields equimolar amounts of oxyntomodulin, glicentin, GLP-1 and GLP-2. 16 The 
Peripheral GLP-1 in energy homeostasis
A meta-analysis summarising nine human physiological studies of appetite and feeding in lean as well as obese subjects with or without impaired glycaemic control concluded that intravenous infusion of bioactive GLP-1 triggers dose-dependent anorexia and subjective loss of appetite. 26 The first unequivocal evidence that GLP-1 mediates negative energy balance and weight loss in humans was provided by a study in subjects with type 2 diabetes in whom GLP-1 was infused subcutaneously for 6 weeks. 27 Zander and colleagues demonstrated that in addition to markedly improving glycaemic control, chronic infusion of GLP-1 (4.8 pmol·kg
) for 6 weeks was associated with a modest weight loss of 1.9 kg. The weight loss induced by peripheral administration of GLP-1 was predominantly due to decreased appetite, as GLP-1-treated subjects reported significantly decreased hunger and increased satiety and fullness. 27 In rats, chronic administration of the once-daily human GLP-1 agonist liraglutide has no impact on energy expenditure. 7, 28 However, in obese mini pigs, chronic dosing with liraglutide leads to a sustained drop in food intake throughout the administration period. 29 Detailed analysis of meal structure revealed that GLP-1 agonists led to premature satiety and hence intake of smaller, and perhaps fewer meals. Several observations support a model characterised by a peripheral as well as a central GLP-1 sensitive system associated with decreased hunger and hence negative energy balance. Keeping in mind that MSG-lesioned rats are insensitive to central administration of GLP-1, 21 Larsen et al. examined the anorectic effects of acute as well as subchronic peripheral administration of the GLP-1 receptor agonist liraglutide. 7 Liraglutide induced dose-dependent anorexia and weight loss to the same degree in MSG-lesioned and normal rats. 7 This finding suggested that GLP-1 receptors other than those present in the arcuate nucleus are responsible for peripherally mediating GLP-1 agonist-induced anorexia. 7 It seems most likely that GLP-1 receptors triggering peripherally induced anorexia are located outside the blood-brain barrier, as GLP-1 shows poor penetration into the brain. 30 However, exendin-4 penetrates the blood-brain barrier more readily and hence physiological experiments with this agent may have to be interpreted differently. 31 It seems rather unlikely that either the once-daily GLP-1 analog liraglutide or the larger GLP-1 agonist molecules such as albugon and PC-DAC-exendin-4 will trigger anorexia via GLP-1 receptors normally shielded by the blood-brain barrier.
The major source of circulating bioactive GLP-1 is the enteroendocrine L cell of the small and large intestine. These cells synthesise the preproglucagon-derived peptides oxyntomodulin, GLP-1 and GLP-2 in parallel with PYY. Peripherally administered bioactive GLP-1 is short lasting as it is rapidly degraded by the enzyme DPP-4. 32 Paradoxically, endogenous GLP-1 released from L cells is degraded at an incredibly fast pace as both the brush border epithelium as well as the endothelial lining of the capillaries present in the stromal core of the villus express high levels of DPP-4. 33 According to one estimate under 20% of newly secreted GLP-1(7-36NH 2 ) actually reaches the systemic circulation because intestinal DPP-4 and hepatic proteases aggressively degrade the active form of GLP-1. 32 Therefore, it is tempting to speculate that GLP-1(7-36NH 2 ) exerts its major physiological action at sites very close to its site of release, i.e. the L cell.
In the periphery, mRNA encoding the GLP-1 receptor gene is found mainly in the endocrine pancreas, gastrointestinal tract, lung and the kidney. 34 Given the involvement of peripheral sensory nerve fibres in mediating the incretin role of GLP-1, however, the putative expression of GLP-1 binding sites upon vagal afferents has recently attracted a great deal of interest. The underlying pharmacodynamic mechanism of action of GLP-1 agonists upon insulin secretion most likely occurs via direct activation of β cells. However, there is ample evidence to support the possibility that vagal sensory afferents are also involved in triggering secretory β-cell response to meal-related spikes of endogenous GLP-1. Thus, administration of GLP-1 directly into the portal vein markedly increases neuronal firing in vagal efferents innervating the pancreas; this activity is completely abolished upon severing the afferents in the hepatic branch of the vagal nerve. 35 Intraportal administration of GLP-1 potentiates the insulin response to an intraportal glucose load much more potently than systemic GLP-1 infusion. This response is also dependent on intact autonomic innervation of the pancreas. These observations support the existence of a reflex arch mediating GLP-1 effects on endocrine responses. 36 The nature of GLP-1 sensitive sites in the liver is being assessed. There is good experimental evidence that the hepatoportal region is equipped with a glucose sensor that is also sensitive to GLP-1, but it is also evident that vagal afferents innervating the liver as well as other parts of the gastrointestinal tract express functional GLP-1 receptors. 37, 38 Thus a large proportion of GLP-1 binding in the ileum and colon could be present on vagal nerve fibres originating in the nodose ganglion (figure 2).
The vagal afferents are, however, not the only entry of GLP-1 signalling to the central nervous system, as all blood-brainbarrier-free areas of the central nervous system are endowed with high densities of GLP-1 receptors. 17 Thus, activation of central pathways involved in appetite regulation by peripheral GLP-1 is possible via the vagus nerve, as well as directly via the area postrema and the median eminence. 16, 39 Peripheral administration of GLP-1 agonists induces activation of the area postrema, the subpostrema area and the dorsomedial part of the nucleus of the solitary tract (figure 3). It is worth noting that preclinical studies with rodents should be interpreted with some caution regarding whether they have been conducted with native GLP-1(7-36NH 2 ) or DPP-4 inhibitor-resistant GLP-1 agonists such as exendin-4. In rats, systemic administration of excessive doses of exendin-4 induces avoidance behaviour and is accompanied by a massive sympathetic reaction with elevated blood pressure, 40 whereas systemic application of native bioactive GLP-1 induces a transient drop in food intake that may not be accompanied by taste aversion or activation of the sympathetic nervous system. 7 Essentially all peptides synthesised within enteroendocrine L cells of the ileum and colon are released upon ingestion of a meal, with a spike proportional to the ingested nutrient load. However, less is known about the stimuli triggering the secretory response of L cells. As the timing of the GLP-1 spike is clearly later than might be expected from a cephalic response to ingestion, research focus has been mainly on nutrients and local paracrine control. In normal human subjects, circulating levels of plasma GLP-1 are transiently elevated upon ileal instillation of 60 kcal of carbohydrate or lipid solutions, and the rise of plasma GLP-1 is tightly correlated to decreased gastric emptying. 41 Some evidence suggests that fat, particularly monounsaturated fat, has a more potent effect than carbohydrates in stimulating L cell release of GLP-1, but additional work is needed to confirm these observations. 42, 43 Also, protein hydrolysates increase L cell release of GLP-1, which is accompanied by increased proglucagon mRNA expression. 44 The molecular mechanisms linking luminal presence of nutrients to increased secretory activity of L cells are far from understood. However, with the identification in L cells of a family of G-protein-coupled receptors having fatty acids as their endogenous ligand, further light has been shed on this issue. In rats and humans, enteroendocrine L cells express GPR120 receptors, which are activated by unsaturated longchain fatty acids; it remains to be established whether ingested fat similarly activates these receptors. 45 The luminal sodium/glucose transporter SGLT-1 is required to promote intestinal GLP-1 release. This suggests that absorption of glucose is more important than contact of glucose with ileal epithelium for the response. 46, 47 However, understanding of the coupling of carbohydrate, particularly sweet-tasting sugars, to GLP-1 secretion has recently been expanded by the discovery of taste receptors and their signalling pathways in the epithelial cells of the small intestine. 48 To become functional, taste receptor proteins form dimers that depend on their composition to promote the taste of bitter, sweet and umami. The L cells express functional components of tasting receptors for sweet and bitter, and sweet-tasting elements, such as glucose, sucrose and sucralose, trigger GLP-1 release from the enteroendocrine cell line NCI-H716 in a dose-dependent fashion. 49 Interestingly, upon blockade of T1R2/T1R3 taste receptor dimers with lactisole, the GLP-1-releasing efficacy of the non-caloric sweetener sucralose is completely lost, confirming the specificity of the response. Gustducin a is a G protein that is one of many downstream intracellular signalling mediators of taste receptor dimers. In genetically modified mice lacking expression of gustducin, sucrose has no incretin effect, which indicates that taste-receptor-mediated Results of these studies have provided scientists with new directions for increasing our understanding of how certain foods convey more powerful incretin actions than others irrespective of their caloric density.
Physiological impact of GLP
Once released, GLP-1 influences diverse physiological actions, most of which are involved in energy homeostasis. Continuous elevation of plasma GLP-1 (110±14 pmol/L), via intravenous infusion of the bioactive tGLP-1(78-107 amide) significantly reduces gastric emptying and gastric acid secretion. 10 Thus, it appears that the peptide acts as a prandially activated ileal brake on the stomach. In humans, the inhibitory action of GLP-1 (7-36) upon gastric motility is partly dependent on an intact vagus nerve, as it is significantly diminished in people with severed vagal innervation of the stomach. 50 It seems intuitively obvious, then, to conclude that the dyspepsia occurring as a result of decreased gastric emptying and gastric acid secretion would lead to decreased hunger and premature satiety, with the greatest impact in the fed state. However, because peripheral administration of GLP-1 agonists also leads to decreased hunger and increased satiety in both the fed and fasted state, it appears that retarded gastric emptying is not the sole explanation of GLP-1-induced anorexia.
Decreasing levels of certain nutrients are important components of onset of feeding and short-term regulation of energy homeostasis. The central nervous system reacts to decreased plasma levels of glucose and lipids with robust feeding responses. These phenomena are described as glucoprivic and lipoprivic feeding, respectively. Lipoprivic feeding may be elicited by an hepatic sensor, although sensory neurons responsible for lipoprivic feeding may also be distributed more widely in the abdominal viscera. Lipoprivic feeding requires intact vagal innervation of these structures to execute its action on central feeding pathways. 51, 52 In contrast, glucoprivic feeding is elicited via glucose-sensitive neurons in areas of the lower brainstem where high densities of GLP-1 binding sites are present. 17, 53 Thus, it is tempting to speculate that circulating levels of GLP-1 could also negatively influence feeding responses elicited by lowered availability of nutrients.
In this context, it is interesting that various gastric weightloss surgeries lead to increased postprandial release of appetite suppressant hormones such as GLP-1 and PYY. In one of the first comprehensive studies of this phenomenon, Näslund and colleagues showed that patients who had undergone jejunoileal bypass surgery as a therapeutic intervention against morbid obesity (body mass index > 40 kg/m 2 ) displayed marked elevations of meal-induced and fasting plasma GLP-1 and PYY. 54 The beneficial impact of gastric bypass surgery on meal-induced rises in plasma GLP-1 and PYY became more pronounced as time passed; thus, it appears that surgical intervention provides sustained improvement in metabolic control in severe obesity. 55 In fact, it is possible that the beneficial impact of gastric bypass surgery on energy homeostasis is ascribable not so much to mechanical food restriction as to the altered postprandial release pattern of anorectic gastrointestinal tract hormones like GLP-1 and PYY. Formal studies of appetite sensation before and after gastric bypass surgery are sparse but patients who have undergone obesity surgery report marked drops in hunger, as well as an earlier onset of meal-induced satiety. 56 In addition, we need studies assessing appetite in gastric bypass subjects to whom GLP-1 receptor antagonists are administered prior to intake of a meal. In patients who have undergone gastric bypass surgery, elevated plasma levels of GLP-1 are unlikely to mediate appetite suppression via changed gastric motility. This supports the theory that surgery leads to alterations in central pathways involved in appetite regulation.
Some controversy has existed as to whether impaired postprandial release of GLP-1 and other incretin hormones play a pathophysiological role in impaired glucose tolerance. In one of the first studies addressing this issue, Fukase and colleagues demonstrated that obese subjects with mild diabetes responded to an oral glucose tolerance test with excessive GLP-1 secretion. 57 In contrast, a number of subsequent studies have reached different conclusions. For example, Ranganath and colleagues demonstrated that postprandial GLP-1 secretion was lower in healthy obese than in healthy lean subjects given a carbohydrate-rich meal, but no between-group differences in GLP-1 secretions were seen after a fat-rich meal. 58 Likewise, in a well-controlled study, Vilsbøll and colleagues gave either small (260 kcal) or large (520 kcal) meals to normal weight or obese healthy subjects, and subjects with type 1 or type 2 diabetes. All four groups demonstrated increases in GLP-1 and GIP levels after ingestion of both meals, with significantly higher concentrations seen in all groups after the large meal. However, subjects with type 2 diabetes displayed a diminished postprandial plasma GLP-1 response compared with matched healthy obese subjects, whereas glucose-dependent insulinotropic polypeptide responses were normal in all groups. 59 Therefore, it seems evident that impaired mealinduced GLP-1 secretion could in part explain dysfunctional eating patterns seen in many obese subjects. 59 
Weight loss in clinical studies of GLP-1 agonists and DPP-4 inhibitors
With the availability of GLP-1 agonists and DPP-4 inhibitors for clinical treatment of type 2 diabetes, it has become evident that the two classes of agents exert a differential impact on energy homeostasis. People with type 2 diabetes using the GLP-1 agonist exenatide have been shown to maintain an average weight loss of 5.3 kg for 3.5 years. 9 Similarly, albeit in shorter studies, the GLP-1 agonist liraglutide has shown significant weight loss (-2.99 kg on liraglutide 1.9 mg/day vs. -1.21 kg on placebo, p=0.039) when given for 14 weeks as monotherapy to 163 subjects with type 2 diabetes. 60 Clinical experience with use of DPP-4 inhibitors clearly differs from that with GLP-1 agonists. The DPP-4 inhibitors yield slightly lesser improvement of glycaemic control than seen with exenatide and liraglutide, although head-to-head comparative THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE S S3 39 9 trials are needed before any conclusions can be drawn with certainty. However, to date, no clinical trial with sitagliptin or vildagliptin has provided evidence that complete inhibition of plasma DPP-4 induces weight loss in people with type 2 diabetes. 61 This might seem a little surprising, as mice genetically modified to have no expression of DPP-4 resist developing dietinduced obesity and impaired glycaemic control. 62 It might simply be that the increase in plasma levels of GLP-1 obtained with maximal inhibition of DPP-4 is insufficient to induce weight loss but sufficient to prevent further weight gain in obese subjects with type 2 diabetes. Even maintenance of body weight in people with impaired glycaemic control and type 2 diabetes constitutes a marked advantage for their metabolic status. The DPP-4 inhibitors may provide an interesting alternative to the sulphonylureas as oral anti-diabetic treatments to be used in combination with other oral agents, such as metformin and the thiazolidinediones. For example, the combination of the DDP-4 inhibitor vildagliptin and peroxisome proliferator-activated receptor γ agonist pioglitazone appears to provide better glycaemic control without an increase in body weight in comparison with either agent alone.
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Conclusion
The endogenous GLP-1 system appears to be highly complex. Several lines of evidence suggest that the peripheral GLP-1-sensitive system feeds into the central GLP-1 pathways, thereby organising the processing mode of the two systems in series rather than in parallel. Both as a hormone and as a neurotransmitter, GLP-1 has a positive impact on energy homeostasis that leads to weight loss and improved metabolic control. This knowledge can be exploited therapeutically for both obese people and subjects with type 2 diabetes. At present, the GLP-1 agonists seem to be a desirable option for treatment of type 2 diabetes, as they improve glycaemic control, improve pancreatic function and induce clinically meaningful weight loss. Taken together, GLP-1 agonists have the potential to modify type 2 diabetes disease progression.
